{"id":"NCT00996437","sponsor":"Jaeb Center for Health Research","briefTitle":"Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)","officialTitle":"An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-06","primaryCompletion":"2012-02","completion":"2013-01","firstPosted":"2009-10-16","resultsPosted":"2013-05-16","lastUpdate":"2016-08-26"},"enrollment":261,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Vitreous Hemorrhage","Proliferative Diabetic Retinopathy"],"interventions":[{"type":"DRUG","name":"Ranibizumab","otherNames":["Lucentis"]},{"type":"DRUG","name":"Saline","otherNames":[]}],"arms":[{"label":"Saline Injection","type":"PLACEBO_COMPARATOR"},{"label":"Ranibizumab","type":"ACTIVE_COMPARATOR"}],"summary":"This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eyes presenting with vitreous hemorrhage from proliferative diabetic retinopathy.","primaryOutcome":{"measure":"Treatment or \"Failure\" Defined as Vitrectomy","timeFrame":"within 112 days of randomization","effectByArm":[{"arm":"Ranibizumab","deltaMin":12,"sd":null},{"arm":"Saline Injection","deltaMin":17,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.37"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":67,"countries":["United States"]},"refs":{"pmids":["25010170","23370902"],"seeAlso":["http://www.jaeb.org/"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":125},"commonTop":["Vitreous hemorrhage","Eye pain","Vitreous floaters","Vision blurred","Conjunctival hemorrhage"]}}